|
Novel |
CELSR1 |
cadherin EGF LAG seven-pass G-type receptor 1 |
|
|
|
|
Novel |
KLRC2 |
killer cell lectin like receptor C2 |
- DAP12 interactions
- DAP12 signaling
- DAP12 signaling
|
|
|
|
|
FGFR1 |
fibroblast growth factor receptor 1 |
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 in disease
- Signaling by plasma membrane FGFR1 fusions
|
- Palifermin
- Sorafenib
- Heparin
- 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
- XL999
- 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
- (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
- 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Fostamatinib
- Erdafitinib
- Pemigatinib
- Selpercatinib
- Pralsetinib
|
- Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
- Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
- Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD)
- Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
|
|
|
FGFR2 |
fibroblast growth factor receptor 2 |
- Signaling by FGFR2 amplification mutants
- Activated point mutants of FGFR2
- Signaling by FGFR2 in disease
- Signaling by FGFR2 IIIa TM
- Signaling by FGFR2 fusions
|
- Palifermin
- Thalidomide
- Heparin
- Sucrosofate
- 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin fibroblast (neonatal)
- Foreskin keratinocyte (neonatal)
- Fostamatinib
- Erdafitinib
- Pemigatinib
- Selpercatinib
- Pralsetinib
|
- Gastric cancer
- Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
- Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
|
|
|
FGFR3 |
fibroblast growth factor receptor 3 |
- Signaling by activated point mutants of FGFR3
- FGFR3 mutant receptor activation
- t(4;14) translocations of FGFR3
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
|
- XL999
- Pazopanib
- Ponatinib
- Lenvatinib
- Nintedanib
- Fostamatinib
- Erdafitinib
- Pemigatinib
- Selpercatinib
|
- Bladder cancer
- Multiple myeloma
- Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
- Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
- FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
- CATSHL syndrome
|
|
|
FGFR4 |
fibroblast growth factor receptor 4 |
- PI3K Cascade
- PIP3 activates AKT signaling
- betaKlotho-mediated ligand binding
- FGFR4 mutant receptor activation
- FGFR4 ligand binding and activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade; FGFR4
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR4 signaling
- Signaling by FGFR4 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Heparin
- Ponatinib
- Lenvatinib
- Erdafitinib
- Pemigatinib
|
|
|
|
NCALD |
neurocalcin delta |
- Activation of Ca-permeable Kainate Receptor
|
|
|